Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etakafusp alfa - Asher Biotherapeutics

Next Previous
Drug Profile

Etakafusp alfa - Asher Biotherapeutics

Alternative Names: AB-248

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asher Biotherapeutics
  • Class Anti-infectives; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 06 Oct 2025 AstraZeneca plans a phase Ib/II ALTAIR trial for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Combination therapy) in USA, Belgium, Brazil, China, France, Georgia, Italy, Japan, Malaysia, Moldova, Netherlands, Peru, Poland, Serbia, South Korea, Spain, Taiwan, Thailand and Turkey (IV), in October 2025 (NCT06996782)
  • 16 Jul 2025 Amgen plans a phase I DeLLphi-311 trial for Small cell lung cancer (Combination therapy, Metastatic disease) (IV, Infusion) in July 2025 (NCT07037758)
  • 08 Jan 2025 Efficacy and adverse events data from a phase Ia/Ib trial in Solid tumours released by Asher Biotherapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top